Patients with mild to moderate renal impairment generally do not require dose adjustment, but closer monitoring may be warranted, particularly for signs of gastrointestinal adverse effects that could lead to dehydration and worsening renal function
To put this simply, it wears off - it does not last
This choice reflects cost and stability considerations rather than optimal bioavailability
Because its not FDA-approved, insurance may not cover it, and the quality is ensured through the compounding pharmacys standards rather than an FDA drug approval
However, supplementing solely with folic acid/folate can mask an underlying B12 deficiency
MECHANISM CATEGORIES SAFETY Side effects Generally well-tolerated in trials at the doses tested Injection-site reactions Known interactions Not characterized in Phase 3 Contraindications Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Not FDA-approved as a drug